Research and Development

Home Groups Research and Development

AVXS-101 Is Getting Fast-Tracked Through the Review Process in Japan

Tagged: , ,

Viewing 0 reply threads
  • Author
    Posts
    • April 6, 2018 at 12:50 pm #11482
      SMA News Today Moderator
      Participant

      AVXS-101 has been awarded the SAKIGAKE designation in Japan for the treatment of spinal muscular atrophy (SMA) type 1. This designation will speed the therapy’s development and review process and allow faster license applications in Japan.

      AVXS-101, the lead product candidate of AveXis, is a gene therapy under development for the treatment of SMA type 1 and SMA type 2. It delivers a normal copy of the SMN1 gene to the motor neurons of patients with SMA who carry a faulty SMN1. The therapy is intended to re-establish the production of functional SMN1 in motor neurons, avoiding their degeneration and preventing further muscle weakening and wasting.

      Read more about this exciting news here: “AveXis’ SMA Type 1 Gene Therapy Granted Speedier Review in Japan“

  • Author
    Posts
Viewing 0 reply threads
  • You must be logged in to reply to this topic.

Search forums

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Search in posts
Search in pages
Search in posts
Search in pages

Who’s Online

There are no users currently online


Members

BioNews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2017-2022 All rights reserved.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account